Sanofi Board ousts CEO Christopher Viehbacher

Published: 29-Oct-2014
Finance Pharmaceutical

Chairman Serge Weinberg will take up the role until a replacement is found

Sanofi's Board of Directors ousted Christopher Viehbacher as Chief Executive following a special meeting held this morning (29 October).

Viehbacher, who has been the French drugmaker's CEO for six years, subsequently resigned as a director of the company.

The Board said Sanofi would continue the strategy of international expansion based on research and innovation that it had pursued under Viehbacher and thanked him for helping the Group 'to move through a sensitive and important transition phase'.

Viehbacher's dismissal followed poor relations between the CEO and the Board.

Going forward the Board said Sanofi needs to 'pursue its development with a management aligning the teams, harnessing talents and focusing on execution with a close and confident cooperation with the Board'.

Chairman Serge Weinberg will take on the CEO role until a replacement for Viehbacher has been appointed.

  • Companies:
  • Sanofi
See more

You may also like

Drug Delivery

Sanofi pledges to sell over €10bn in vaccine sales

Read more
In less than two years, Sanofi has delivered a competitive mRNA platform with improved potency and thermostability that performs with both viral and bacterial targets

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  3. Sanofi Pasteur launches 5-in-1 combination vaccine in China New vaccine Pentaxim reduces number of infant injections from 12 to four
  4. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  5. Flexicon optimises Rossix’s small batch filling and capping process Rossix has optimised its batch filling and capping process by using a peristaltic filler of the PF series and a FlexFeed30 tabletop bottle handling and capping system from Flexicon Liquid Filling

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Drug Delivery

Sanofi pledges to sell over €10bn in vaccine sales

In less than two years, Sanofi has delivered a competitive mRNA platform with improved potency and thermostability that performs with both viral and bacterial targets
Drug Delivery

Sanofi acquires Provention Bio and gains diabetes therapy

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Provention Bio through the merger of a wholly owned subsidiary of Sanofi with and into Provention Bio
Regulatory

Sanofi's ALTUVIIIO approved by the US FDA

"This positive event triggers impairment reversal, positively impacting 2022 IFRS net income"
Manufacturing

Sanofi increases evergreen fund to $750m

The additional capital, confirmed by the executive committee, will also fuel the expansion and investment capacity of the Sanofi Ventures
Finance

Neuraxpharm to increase branded business by acquiring established Sanofi products

Neuraxpharm, the central nervous system (CNS) specialist, to acquire two portfolios of established products for CNS disorders, pain and vascular diseases
Research & Development

C4XD receives first milestone payment of €3 million from Sanofi

€3 million milestone payment triggered by preclinical progression in oral IL-17A inhibitor programme
Research & Development

Exscientia and Sanofi establish AI-based research collaboration

The companies will collaborate to identify and select target projects, leveraging Exscientia’s personalised medicine platform, designed to enable a patient-first approach
Subscribe now